Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Rhea-AI Summary
Labcorp (NYSE: LH) announced an expanded collaboration with Epic to offer Labcorp's full test menu through Epic's Aura platform, a unified system for ordering and receiving lab results.
The integration aims to reduce IT complexity, streamline lab ordering within Epic workflows, and expand access to advanced genetic and specialty diagnostics for hospitals and health systems nationwide.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LH
On the day this news was published, LH gained 0.89%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LH is up 0.38% while close peers are mixed: DGX up 1.33%, NTRA up 2.59%, but MTD, WAT, and IQV down between 2.57–3.41%, pointing to stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 01 | New pharma entity | Neutral | -0.4% | Launch of public health–focused Knoa Pharma addressing opioid crisis. |
| Apr 30 | Q1 2026 earnings | Positive | -0.1% | Q1 beat with revenue $3.54B, EPS growth and raised 2026 guidance. |
| Apr 22 | Companion diagnostic launch | Positive | -0.8% | Nationwide rollout of FDA-approved PD-L1 assay for KEYTRUDA ovarian cancer use. |
| Apr 15 | Rapid fentanyl test | Positive | -0.8% | Launch of FDA-cleared 10-minute fentanyl urine test via Labcorp Point of Care. |
| Apr 14 | AI data platform | Positive | +1.8% | AI-powered real-world data platform with AWS and Datavant for Alzheimer’s. |
Recent Labcorp product and technology launches, as well as strong earnings with raised guidance, have often seen muted or negative next-day price moves, indicating a tendency toward cautious market reactions to positive news.
Over the last few months, Labcorp reported strong Q1 2026 results with revenue of $3.54B, raised full‑year guidance, and highlighted growth in diagnostics and biopharma services. It launched an FDA‑approved ovarian cancer companion diagnostic and an FDA‑cleared rapid fentanyl urine test, plus an AI‑powered real‑world data platform for Alzheimer’s research on Apr 14, 2026. Despite these positive developments, several announcements saw flat or negative price reactions, suggesting investors often responded conservatively to good operational news before this Epic integration update.
Market Pulse Summary
This announcement expands Labcorp’s collaboration with Epic so that the company’s full test menu becomes available through the Aura platform, embedding ordering and results into existing electronic health record workflows. It builds on earlier genetic testing integration and aims to reduce IT complexity for hospitals and health systems. In context of recent FDA‑cleared tests, AI initiatives, and raised 2026 guidance, investors may track adoption across Epic clients and future updates on new diagnostics added to Aura as key markers of strategic impact.
Key Terms
electronic health record (ehr) technical
AI-generated analysis. Not financial advice.
- Labcorp's full test menu will be available through Epic's Aura platform
- Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura
- Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide
Reducing Complexity and Expanding Access to Testing and Diagnostic Innovation
Health systems often face lengthy, complex and time-consuming IT projects to integrate with laboratory partners. By leveraging Epic's Aura, the expansion will reduce the time, cost and ongoing maintenance typically required for lab interfaces. Building on the availability of Invitae genetic tests through Aura, part of Labcorp's diagnostic portfolio, health systems will be able to access Labcorp's full test menu and new tests as they are introduced directly within their existing Epic workflows.
"This expanded collaboration reflects how Labcorp is investing to meet the evolving needs of hospitals and health systems," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By simplifying lab integrations and delivering our full test menu directly within Epic workflows, we are expanding access and building a strong foundation for continued innovation."
Benefits for Clinicians and Health Systems
The expanded integration will deliver meaningful benefits including:
- Simplified onboarding and maintenance – Aura's connectivity and content‑management capabilities reduce the effort required to onboard and maintain Labcorp's test menu, reducing integration complexity for hospitals and health systems.
- Seamless access within Epic workflows – Clinicians will be able to order Labcorp tests and receive discrete results directly within their Epic workflow, improving efficiency and reducing reliance on manual processes or workarounds.
- Broader access to Labcorp's full and evolving test menu, including new and advanced diagnostics.
"Expanding Labcorp's use of Aura to include its full test menu makes it easy for clinicians to order the right test the first time, right from their workflow, so patients get accurate answers faster," said Sumit Rana, President of Epic.
To learn more about Labcorp's ongoing collaboration with Epic and future plans to advance diagnostic integration for hospitals and health systems, visit https://www.labcorp.com/organizations/epic.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits of integrating Labcorp's full test menu into the Epic Aura platform.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-and-epic-expand-collaboration-to-advance-diagnostic-integration-across-hospitals-and-health-systems-302768704.html
SOURCE Labcorp